ArticleInternal medicine (Tokyo, Japan)2026
Effective Treatment with an Interleukin-5 Inhibitor for Recurrent Life-threatening Coronary Spastic Angina with Hypereosinophilia.
Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Do Not Overlook the Existence of Specific Coronary Spasms, Which Are Often Juvenile and Refractory: Eosinophilia-associated Coronary Spasm.Internal medicine (Tokyo, Japan) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 39-year-old man with asthma and chronic sinusitis presented with nocturnal chest pain and a loss of consciousness. Blood tests showed elevated myocardial enzyme levels and eosinophilia, but the coronary angiography results were unremarkable. Although the patient was treated with vasodilators, chest pain with ST elevation recurred, leading to a diagnosis of refractory coronary spastic angina (CSA) with hypereosinophilia. Prednisolone (PSL) was initially effective, but symptoms recurred during dose reduction. After initiation of mepolizumab, an interleukin-5 (IL-5) inhibitor, his symptoms improved, allowing tapering of PSL. This case indicates that IL-5 inhibitors can be useful glucocorticoid-sparing agents for recurrent CSA associated with eosinophilia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.